Revolutionary new Continuous Glucose
Monitoring System eliminates fingersticks* for people with
diabetes
VANCOUVER, Sept. 9, 2019 /CNW/ - DexCom Inc.
(NASDAQ:DXCM), a leader in continuous glucose monitoring (CGM),
announced today that it is now accepting orders for the Dexcom G6
CGM System for people with diabetes ages two years and up.
"We are thrilled to offer the Dexcom G6 Continuous Glucose
Monitoring (CGM) System to Canadians and are proud of this
innovative technology that enables more effective diabetes
management," said Laura Endres, Vice
President and General Manager, Dexcom Canada, Inc. "The Dexcom G6
not only frees people with diabetes from the burden of
fingersticks, but also offers real-time alerts and other features
that can help people make more informed decisions for their daily
diabetes management. This product changes people's
lives."
The Dexcom G6 is now available and builds upon the core
attributes of the Dexcom G5 Mobile CGM technology platform, while
introducing new features that empower users to take control of
their diabetes:
- Elimination of fingersticks for calibration and diabetes
treatment decisions*
- Continuous glucose readings sent automatically using Bluetooth
technology to any compatible smart device†, or to a Dexcom
receiver, at five-minute intervals
- Customizable alerts and alarms, including a new Urgent Low Soon
alert which can warn users up to 20 minutes in advance of an urgent
hypoglycemic event, so they can take steps to prevent it
- Real-time data sharing with the Dexcom G6 app, allowing the
user to share their glucose data with up to five followers to
monitor their glucose levels remotely for extra peace of mind
- 10-day sensor allowing for longer wear (3 days longer than
the previous generation Dexcom CGM)
- A slimmer transmitter with a lower profile for more discreet
wear ability
- An auto-applicator designed to make sensor insertion simple
with the touch of a button
- A newly designed receiver with a touchscreen display (optional
display device)
- New sensor membrane that enables acetaminophen use without any
effect on glucose readingsǂ
"It is an exciting time for diabetes management, as new
advancements in diabetes monitoring technology allow patients to
move away from the traditional fingerstick blood glucose monitoring
to continuous blood glucose monitoring" said Dr. Rémi
Rabasa-Lhoret, Endocrinologist & Director of the Montreal
Clinical Research Institute Diabetes Clinic. "Rather than multiple
daily checks, patients can now have access to real-time detailed
blood glucose profiles with alarms, allowing them to prevent and
treat both low and high blood glucose levels - enabling easier and
more informed therapeutic decisions. These devices are key to
achieve recommended therapeutic goals more safely and
easily. The Dexcom G6 is another advancement for glucose
monitoring - allowing 10 days of wireless glucose monitoring
without fingersticks, using an accurate, small and easy to use
device."
In Canada, both current and new
CGM users can now purchase a Dexcom G6 CGM starter kit at the
Dexcom Store online at www.dexcom.com.
More information on Dexcom G6 can be found at
www.dexcom.com.
About Dexcom G6
The Dexcom G6 is a stand-alone CGM
system for people with diabetes who use insulin – who administer
insulin either with multiple daily injections or an insulin pump.
With the Dexcom G6, the sensor is worn separately from an insulin
pump and is inserted under the skin to measure the level of glucose
in the interstitial fluid (fluid in the tissue). The sensor is
disposable and should be changed every 10 days.
About CGM
CGM devices are considered the most
significant breakthrough in diabetes management in the past 40
years1 and Dexcom has been a leader of those
innovations. Type 1 diabetes affects nearly 300,000
Canadians2. The traditional standard-of-care for glucose
monitoring has been a fingerstick meter, which is painful as some
patients needed to test their blood up to 12 times a day. CGM is
important because, in addition to providing the glucose level, it
provides the direction and rate of glucose change at a glance and
alerts users when glucose levels are too low or too high. People
with diabetes who take insulin must monitor their blood glucose
levels frequently to manage their condition. Uncontrolled glucose
can cause serious health complications and even
death3,4. To learn more about CGM, visit
www.dexcom.com.
About Dexcom, Inc.
Dexcom, Inc., headquartered
in San Diego, CA, and has operations in Canada, is
dedicated to helping people better manage their diabetes by
developing and marketing continuous glucose monitoring (CGM)
products and tools for adult and pediatric patients. With
exceptional performance, patient comfort and lifestyle flexibility
at the heart of its technology, users have consistently
ranked Dexcom highest in customer satisfaction and
loyalty.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
*If your glucose
alerts and readings from the G6 do not match symptoms or
expectations, use a blood glucose meter to make diabetes treatment
decisions.
|
|
†To view a list of
compatible devices, visit www.dexcom.com/compatibility
|
|
ǂ G6 readings can be
used to make diabetes treatment decisions when taking up to a
maximum acetaminophen dose of 1,000mg every six hours. Taking a
higher dose may affect the G6 readings.
|
|
|
1 Clarke SF and Foster JR. A history
of blood glucose meters and their role in self-monitoring of
diabetes mellitus. Br J Biomed Sci. 2012;(3)2:83-93.
|
|
2 Canadian
Diabetes Association. The prevalence and costs of diabetes.
December 2009.
|
|
3
Hyperglycemia (High blood glucose). American Diabetes Association
Web site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hyperglycemia.html.
Updated August 5, 2013. Accessed December 3, 2013.
|
|
4
Hypoglycemia (Low blood glucose). American Diabetes Association Web
site.
http://www.diabetes.org/living-with-diabetes/treatment-and-care/blood-glucose-control/hypoglycemia-low-blood.html.
Updated July 16, 2013. Accessed December 3, 2013.
|
SOURCE Dexcom, Inc.